Jeffrey W. Albers Sells 6,349 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Jeffrey W. Albers sold 6,349 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Kymera Therapeutics Stock Down 1.0%

Shares of NASDAQ KYMR traded down $0.50 during mid-day trading on Friday, reaching $47.16. 519,950 shares of the company were exchanged, compared to its average volume of 608,724. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The company's 50 day moving average price is $29.81 and its 200 day moving average price is $35.74. The stock has a market capitalization of $3.07 billion, a PE ratio of -20.24 and a beta of 2.07.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm's revenue for the quarter was up 114.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.69) earnings per share. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently bought and sold shares of the business. Blue Trust Inc. grew its holdings in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after acquiring an additional 270 shares during the period. KBC Group NV increased its position in shares of Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after purchasing an additional 328 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares during the last quarter. Comerica Bank lifted its stake in shares of Kymera Therapeutics by 3.6% in the 1st quarter. Comerica Bank now owns 21,374 shares of the company's stock worth $585,000 after purchasing an additional 743 shares during the period. Finally, Hsbc Holdings PLC boosted its holdings in shares of Kymera Therapeutics by 6.1% in the first quarter. Hsbc Holdings PLC now owns 18,547 shares of the company's stock worth $508,000 after buying an additional 1,064 shares during the last quarter.

Analysts Set New Price Targets

KYMR has been the subject of a number of research reports. Morgan Stanley raised shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $49.00 to $79.00 in a research note on Tuesday. JPMorgan Chase & Co. lifted their price objective on Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday. HC Wainwright boosted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, February 28th. UBS Group cut their price target on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, B. Riley upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the company from $38.00 to $60.00 in a report on Tuesday. Two analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $59.82.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.